| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
* Department of Cell Biology and Anatomy, Faculty of Medicine, and Department of Biological Sciences, Faculty of Science, University of Calgary, Calgary, Alberta, Canada; and Institute of Applied Photophysics, University of Technology Dresden, Dresden, Germany
Correspondence: Address reprint requests to M. W. Amrein, Tel.: 403-210-8177; E-mail: mamrein{at}ucalgary.ca.
In adult respiratory distress syndrome, the primary function of pulmonary surfactant to strongly reduce the surface tension of the air-alveolar interface is impaired, resulting in diminished lung compliance, a decreased lung volume, and severe hypoxemia. Dysfunction coincides with an increased level of cholesterol in surfactant which on its own or together with other factors causes surfactant failure. In the current study, we investigated by atomic force microscopy and Kelvin-probe force microscopy how the increased level of cholesterol disrupts the assembly of an efficient film. Functional surfactant films underwent a monolayer-bilayer conversion upon contraction and resulted in a film with lipid bilayer stacks, scattered over a lipid monolayer. Large stacks were at positive electrical potential, small stacks at negative potential with respect to the surrounding monolayer areas. Dysfunctional films formed only few stacks. The surface potential of the occasional stacks was also not different from the surrounding monolayer. Based on film topology and potential distribution, we propose a mechanism for formation of stacked bilayer patches whereby the helical surfactant-associated protein SP-C becomes inserted into the bilayers with defined polarity. We discuss the functional role of the stacks as mechanically reinforcing elements and how an elevated level of cholesterol inhibits the formation of the stacks. This offers a simple biophysical explanation for surfactant inhibition in adult respiratory distress syndrome and possible targets for treatment.
This article has been cited by other articles:
 |
|
 |
|
  Y. Y. Zuo, S. M. Tadayyon, E. Keating, L. Zhao, R. A. W. Veldhuizen, N. O. Petersen, M. W. Amrein, and F. Possmayer Atomic Force Microscopy Studies of Functional and Dysfunctional Pulmonary Surfactant Films, II: Albumin-Inhibited Pulmonary Surfactant Films and the Effect of SP-A Biophys. J., September 15, 2008; 95(6): 2779 - 2791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Y. Zuo, E. Keating, L. Zhao, S. M. Tadayyon, R. A. W. Veldhuizen, N. O. Petersen, and F. Possmayer Atomic Force Microscopy Studies of Functional and Dysfunctional Pulmonary Surfactant Films. I. Micro- and Nanostructures of Functional Pulmonary Surfactant Films and the Effect of SP-A Biophys. J., May 1, 2008; 94(9): 3549 - 3564. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Maruscak, D. W. Vockeroth, B. Girardi, T. Sheikh, F. Possmayer, J. F. Lewis, and R. A. W. Veldhuizen Alterations to surfactant precede physiological deterioration during high tidal volume ventilation Am J Physiol Lung Cell Mol Physiol, May 1, 2008; 294(5): L974 - L983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Baoukina, L. Monticelli, M. Amrein, and D. P. Tieleman The Molecular Mechanism of Monolayer-Bilayer Transformations of Lung Surfactant from Molecular Dynamics Simulations Biophys. J., December 1, 2007; 93(11): 3775 - 3782. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
